Logo

ROIV

Roivant Sciences Ltd.

ROIV

Roivant Sciences Ltd. • NASDAQ
$20.81 ▼ -0.29% (-0.06)
Market Cap $14.47 B
52w High $21.35
52w Low $8.73
Dividend Yield 0%
P/E -21.02
Volume 2.35M
Outstanding Shares 695.49M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q2-2025 $1.571M ▼ $307.693M ▲ $-113.519M ▲ -7.226K% ▲ $-0.17 ▲ $-158.122M ▲
Q1-2025 $2.17M ▼ $286.938M ▼ $-223.355M ▼ -10.293K% ▼ $-0.33 ▼ $-283.824M ▼
Q4-2024 $7.57M ▼ $292.33M ▲ $-206.475M ▼ -2.728K% ▼ $-0.29 ▼ $-283.54M ▼
Q3-2024 $9.018M ▲ $283.14M ▼ $169.381M ▲ 1.878K% ▲ $0.23 ▲ $-271.46M ▼
Q2-2024 $4.475M $345.954M $-230.184M -5.144K% $-0.31 $-222.565M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q2-2025 $4.386B ▼ $5.063B ▲ $257.14M ▲ $4.362B ▲
Q1-2025 $4.503B ▼ $5.033B ▼ $216.696M ▼ $4.346B ▼
Q4-2024 $4.887B ▼ $5.437B ▼ $249.742M ▼ $4.688B ▼
Q3-2024 $5.147B ▼ $5.792B ▼ $256.375M ▼ $5.189B ▲
Q2-2024 $5.387B $6.206B $625.986M $5.153B

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q2-2025 $-113.519M ▲ $-185.664M ▲ $120.422M ▲ $62.587M ▲ $-1.449M ▲ $-193.512M ▲
Q1-2025 $-273.911M ▼ $-204.383M ▼ $-1.086B ▼ $-187.768M ▼ $-1.477B ▼ $-208.418M ▼
Q4-2024 $-252.375M ▼ $-172.565M ▲ $1.074B ▲ $-177.153M ▲ $723.987M ▲ $-173.376M ▲
Q3-2024 $118.075M ▲ $-207.251M ▲ $454.074M ▲ $-272.951M ▼ $-27.195M ▲ $-209.078M ▲
Q2-2024 $-279.924M $-266.806M $-3.294B $-109.074M $-3.664B $-267.802M

Revenue by Products

Product Q2-2023Q2-2024Q3-2024Q1-2025
Product Revenue Net
Product Revenue Net
 $20.00M ▲$20.00M ▲$20.00M ▲$20.00M ▲

Five-Year Company Overview

Income Statement

Income Statement Roivant still looks like a development‑stage biotech from a P&L perspective. Underlying product revenue is very small, and the business continues to run at an operating loss when you strip out deal‑related gains. The sharp swing to a large profit in 2023 appears driven mainly by one‑off transactions (like the Telavant sale), not by recurring operations. In 2024, results move back toward losses, which underscores how reliant reported earnings are on deals rather than a mature, diversified revenue base. Overall, the income statement shows a company investing heavily ahead of potential future product and royalty streams, with inherently lumpy results.

Balance Sheet

Balance Sheet The balance sheet is a clear strength. Roivant holds a large cash position relative to its size, and uses very little debt, giving it financial flexibility and reducing balance‑sheet risk. Equity has grown meaningfully over time, helped by successful asset monetizations, which provides a cushion to absorb ongoing R&D spending and setbacks. The drop in cash from the peak simply reflects spending and capital deployment rather than stress, based on the data provided. In short, the company looks well‑capitalized for a biotech that is still building out its commercial footprint.

Cash Flow

Cash Flow Cash flow tells the classic early‑stage biotech story: steady cash burn from operations and negative free cash flow. Most of the outflow is tied to R&D and overhead, not to heavy capital spending, which remains minimal. This means Roivant’s cash needs are driven by the pace and scale of its development programs, rather than factories or equipment. The combination of significant cash on hand and ongoing burn suggests a multi‑year runway, but still leaves the business dependent on future partnerships, milestone payments, and eventually product sales to move toward self‑funding.

Competitive Edge

Competitive Edge Roivant’s edge comes from its unconventional structure and proven deal‑making. The “Vant” model creates focused, semi‑independent units around specific drugs or therapeutic areas, which can move faster and be more specialized than a traditional big pharma division. Roivant has shown it can identify overlooked or deprioritized assets from larger companies, progress them, and then crystallize value through sales or partnerships, as seen with Telavant. This strategy, combined with a strong balance sheet, gives Roivant bargaining power when negotiating future deals. The flip side is that its success is tightly linked to sourcing attractive assets, executing in the clinic, and maintaining productive relationships with big pharma partners.

Innovation and R&D

Innovation and R&D Innovation is central to Roivant’s identity. The company marries its Vant structure with a tech‑forward approach, using AI, advanced computational platforms, and data analytics (for example via Lokavant) to try to design better trials and pick more promising drug candidates. Its track record includes multiple FDA approvals and a commercial product in VTAMA for psoriasis, which shows the model can produce real therapies, not just concepts. The pipeline spans different drug types and disease areas, with notable late‑stage and potentially registrational programs like brepocitinib and next‑generation FcRn antibodies highlighted in the provided information. Still, as with any biotech, every program faces clinical, regulatory, and competitive uncertainty, and a few key assets can drive a large share of perceived value.

Summary

Roivant is best viewed as a platform‑style biopharma company that uses capital, structure, and technology to recycle under‑appreciated drug assets into focused “Vants.” Financially, it remains loss‑making on an operating basis, but is supported by a strong cash position and very low debt, giving it time to execute its strategy. Cash flows are negative but manageable given the current cash war chest, with spending concentrated in R&D rather than heavy infrastructure. Competitively, Roivant stands out for its agile model, proven ability to monetize assets through large strategic deals, and a diversified, late‑stage pipeline, yet it remains highly exposed to clinical trial outcomes and deal timing. Overall, it is an innovation‑driven, event‑driven story where future value will hinge on the success of a handful of key programs and the company’s continued ability to source and scale attractive assets within its Vant ecosystem.

NEWS

November 10, 2025 · 7:00 AM UTC

Roivant Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Business Update

Read more

October 27, 2025 · 4:10 PM UTC

Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025

Read more

September 17, 2025 · 7:00 AM UTC

Roivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM)

Read more

September 11, 2025 · 4:30 PM UTC

Roivant Named on Fortune Media and Great Place To Work's 2025 Best Workplaces in BioPharma List

Read more

September 4, 2025 · 7:00 AM UTC

Pulmovant Receives Orphan Drug Designation in Japan for Mosliciguat for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

Read more